Replies to post #29262 on OncoSec Medical Inc (ONCSQ)

[lasers]

mybikeisorange I totally disagree with you.

Shareholders accept the true guidance of Dr. Robert Pierce and what his goals and planning are. As a medical science person I concur exactly with Dr. Pierce from the 1st day he joined $ONCS. The plan is very simple in making $ONCS Melanoma next trial a Pivotal P2B Combo with Merck's Keytruda and then apply for a Commercial BLA.

As I have stated it is absolutely unprecedented that the FDA has allowed $ONCS to proceed from a safety/tolerability P1/2A EP+IL-12 directly to an efficacy Combo P2B Keytruda + EP+IL-12.

To science medical persons this means that Dr. Pierce and the FDA have worked on an agreed Protocol for which the expected successful results in greater ORR for the Combo vs either alone will lead to Commercial BLA approval of $ONCS EP+IL-12 as an adjunct with Keytruda.